

Asian Journal of Cardiology Research

4(3): 1-7, 2021; Article no.AJCR.67253

Successful Management of Acute Coronary Syndrome with Cardiogenic Shock, Severe Mitral Regurgitation and Multi-organ Dysfunction: A Case Report

Yash Paul Sharma[1], Krishna Prasad[1], Navjyot Kaur[1], C. R. Pruthvi[1], Anil Chaudhray[1] and Prashant Panda[1*]

[1]Department of Cardiology, Post Graduate Institute of Medical Education & Research, Chandigarh-160012, India.

Authors' contributions

This work was carried out in collaboration among all authors. Author YPS was the primary physician who managed the patient, did final review and editing. Authors KP, NK, CRP and AC did the literature review, wrote protocol and produced first draft of manuscript. Author PP was involved in planning the study, in conceptualization & methodology along with supervision, final review and editing. All authors read and approved the final manuscript.

Article Information

Editor(s):
(1) Dr. Hugo R. Ramos, Hospital de Urgencias, Argentina.
Reviewers:
(1) Larisa Anghel, Grigore T. Popa University of Medicine and Pharmacy, Romania.
(2) Saura Ouriel, Centre Hospitalier Universitaire de Lille (CHU Lille), France.
Complete Peer review History: http://www.sdiarticle4.com/review-history/67253

Case Study

Received 02 February 2021
Accepted 07 April 2021
Published 19 April 2021

ABSTRACT

Acute coronary syndrome (ACS) with cardiogenic shock has worst prognosis. Early revascularization has been shown to be beneficial in cases who present early; but many a times, patients present late after ACS and their hemodynamics is compromised by systemic inflammatory response syndrome and multi-organ dysfunction. We hereby present a case of anterior wall myocardial infarction with severe left ventricular systolic dysfunction (left ventricular ejection fraction (LVEF):27%) and severe secondary mitral regurgitation (MR), who presented late after ACS and was in cardiogenic shock, pulmonary edema and had acute kidney injury on presentation. The patient was initially managed conservatively with dual oral antiplatelets, statins, glycoprotein IIb/IIIa inhibitors infusion (tirofiban), parentral anticoagulation, inotropes, diuretics, and

**Corresponding author: Email: prashantpanda85@gmail.com;*

mechanical ventilation. She was taken up for coronary angiography and percutaneous coronary intervention to left anterior descending artery and chronically occluded left circumflex artery during same admission after stabilization of hemodynamics. She tolerated the procedure well and her repeat echocardiogram (done after two weeks) showed LVEF of 50% and mild MR. This case highlights an alternative approach to manage ACS with cardiogenic shock, who presents late after acute event.

Keywords: Acute coronary syndrome; acute kidney injury; anterior wall myocardial infarction, cardiogenic shock; glycoprotein IIb/IIIa inhibitors; multi organ dysfunction syndrome; mitral regurgitation; pulmonary edem.

1. INTRODUCTION

Cardiogenic shock (CS) after acute coronary syndrome (ACS) carries poor prognosis with an estimated mortality of 50 to 60%, despite early revascularization and mechanical circulatory support [1]. Though the SHOCK (Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock) trial seems to justify and recommend early invasive strategy in ACS patients with CS, [2,3] there are many studies which question the safety and benefit of early intervention in this group [4-8]. Besides, this strategy may not be best for the late presenters where the hemodynamics has been further compromised with multi organ dysfunction and systemic inflammatory response syndrome (SIRS). Most of our ACS patients, in developing countries, have delayed presentation and such a cohort of ACS patients with CS & delayed presentation has not been represented well in randomized controlled trials. We hereby describe a case of ST elevation anterior wall myocardial infarction (AWMI) with CS and acute pulmonary edema in Killip class IV, who presented more than 72 hours after symptom onset and was managed successfully with initial conservative approach, followed by revascularization in same admission.

2. CASE PRESENTATION

Fifty years old female, a known case of diabetes type 2, hypertension, chronic kidney disease (baseline creatinine: 2.1 mg/dL) and hypothyroidism presented with acute onset anginal chest pain of 3 days duration associated with class 4 dyspnea and decreased urine output. Her electrocardiogram (ECG) revealed sinus rhythm, ST elevation in V1 to V3 and ST depression in inferolateral leads s/o ST elevation AWMI (as shown in Fig. 1a). At admission, she was in Killip class IV with blood pressure of 84/56 mm of Hg on inotropes (nor adrenaline [maximum dose: 0.08 ug/kg/minute] and dobutamine [maximum dose: 10 ug/kg/minute]), heart rate of 116/minute, respiratory rate of 28/minute, and saturation of 70% at room air. She had bilateral diffuse crackles, gallop rhythm and a soft pan-systolic murmur of grade 3/6 at apex. Echocardiogram revealed severe eccentric mitral regurgitation (MR) with severe hypokinesia in left anterior descending artery (LAD) and left circumflex artery (LCx) and left ventricular ejection fraction (LVEF) of 27%. Reverse transcription polymerase chain reaction (RT-PCR) for COVID-19 was negative. Blood investigations revealed leucocytosis (14900/mm^3), Troponin T of 14.8 pg/ml and BNP of 1232 pg/ml and deranged renal function with creatinine of 3.9 mg/dl and urea of 89 mg/dl. Arterial blood gas showed hypoxia with high anion gap metabolic acidosis (lactic acid 2.4 mmol/l). Chest X-ray showed white out lungs with bat wing appearance suggestive of diffuse pulmonary edema (as shown in Fig. 2a).

She was managed with mechanical ventilation, inotropic support along with dual oral antiplatelets (DAPT), statins, glycoprotein IIb/IIIa infusion (tirofiban), parentral anticoagulation and gastric mucosal protection. Though her inotropes requirement decreased over 48 hours of admission, her hospital stay was complicated with sepsis and worsening of renal functions which was managed as per the guidelines. She responded to the treatment; renal function tests improved (creatinine 4.7 to 2.0 mg/dl), pulmonary edema resolved (as shown in Fig. 2b) with decrease in severity of MR. After hemodynamic stabilization, she was taken up for coronary angiogram which revealed triple vessel disease with diffuse 80% stenosis in left anterior descending (LAD) artery and chronic total occlusion (CTO) of left circumflex artery (LCx) and right coronary artery (RCA) (as shown in Fig. 3 a,b,c and Video 1,2,3). She was offered coronary artery bypass grafting (CABG) as first option for revascularization, however as the patient and relatives were unwilling for open

heart surgery, she was taken up for angioplasty to LAD and LCx and planned for staged ischemia driven revascularization of RCA. LAD lesion was stented with long tapered drug eluting stent (DES) 3.0 x 2.5 x 50 mm (Biomime Morph, Meril life sciences™, India) with TIMI III flow (as shown in Fig. 3d). LCX CTO was successfully crossed with Gaia II (ASAHI™Intech, Aichi, Japan) wire using microcatheter (as shown in Fig. 3e,f) followed by Sion Blue guide wire (ASAHI™Intech, Aichi, Japan). Lesion preparation was initially done with 1.25 x 8 mm semi-complaint balloon, followed by a 2.0 x 20 mm non-compliant (NC) balloon. Two overlapping DES 3 x 32 mm and 2.75 x 20 mm were deployed from proximal to distal LCX and post dilated with 3.0 x 15 mm NC balloon at 14 to 16 atmosphere with TIMI III flow both in LAD and LCX. (as shown in Fig 3g,h). The procedure was uneventful with a total fluoroscopy time of 22 minutes, procedural time of 56 minutes and radiation dose of 524 mGy. Total contrast used was 130 ml. She was continued on DAPT and statins. Two weeks post procedure, her echocardiogram revealed improved LVEF OF 50 % with mild MR (as shown in Fig. 4).

3. DISCUSSION

CS complicates 7-10% cases of ACS and is associated with significant mortality. With better medical care and revascularization, the mortality in ACS with CS has reduced from 70-80% to 40-50% [9,10].Though the SHOCK trial revealed improved survival upto six years with early revascularization, patients in the trial presented to medical set up at much shorter time, such that median time from ACS to shock was 5-6 hours, medial time to intervention after randomization was 1-2 hours. However in real world scenario, especially in developing countries, median time to appropriate care in best of the centers is at least 24 hours [11]. Besides >30% patients with ST elevation myocardial infarction (STEMI) in developing countries scenario are late presenters [12]. A delayed presentation in STEMI is associated with extensive necrosis and worse outcomes [13]. In present COVID era, the delay in presentation of ACS to hospitals is further increased due to fear of contracting viral infection and due to decreased availability of public transport. Since unprepared health care system was overwhelmed with the pandemic, the delay in revascularization was further augmented by unmet needs of logistics and skilled manpower [14,15]. The index patient had chest pain for 3 days before presentation to our center, and additional four hours were required for screening the patient for COVID-19. Though all efforts were made to provide maximum supportive care at earliest medical contact, the activation of catheterization services was often delayed due to obvious logistical reasons [14,15].

ACS with left ventricular dysfunction is the most common cause of CS. A loss of more than 40% of functional myocardium is required to produce CS [16]. Besides mechanical complications like ventricular septal rupture, free wall rupture, and papillary muscle rupture or dysfunction may also contribute to CS after ACS [17]. The patients with CS who survive to discharge have similar outcomes compared to those who have stable hemodynamics, so it is important that their early survival be improved [18]. A long standing shock produces a state of SIRS and MODS further compromising already depressed cardiac mechanical function and leads to a vicious cycle. The late presenters with CS, usually have acidosis, inappropriate vasodilation resistant to vasopressors, compromised renal and lung functions; besides being in a state of inflammation and hypercoagulation. Sepsis was suspected in 18% of the SHOCK cohort and those with culture positive sepsis had twice the risk of death [19]. The most accepted theory of septicemia in these patients is decreased perfusion of intestinal tract which enables transmigration of bacteria into bloodstream [20].

Though early revascularization and mechanical circulatory devices have reduced the mortality in patients of ACS with shock from 80 – 90% to below 50% [21,22]; the mortality in late presenters is still very high and the consensus on management is far from reached. Early invasive management in such patients may further compromise the already depressed cardiac and renal function without any additional advantage.[4-8] Any intervention in such a state has a very high baseline risk of mortality and failure. For same reasons, this subgroup of patients have always been excluded from trials studying the role of early revascularization in ACS [23]. Pre-hospital ambulance thrombolysis or primary percutaneous coronary intervention (within 2 hours of symptoms onset) can remarkably decrease the incidence of cardiogenic shock [24], but for those patients presenting late to the health care facilities, medical stabilization offers a plausible approach with equal rates of in-



Fig. 1a. Electrocardiogram (ECG) showing ST elevation anterior wall myocardial infarction



Fig. 1b. Resolution of ECG changes post PCI



Fig. 2a. Chest X ray showing diffuse infiltrates with bat wing appearance

Fig. 2b. Chest X ray showing radiological resolution following diuretics and mechanical ventilation



Fig. 3a. Right coronary artery showing proximal total occlusion, 3b: Left Circumflex artery showing proximal chronic total occlusion, 3c: Diffusely diseased Left anterior descending artery with a stenosis of maximum 90%, 3d: Post Drug Eluting Stent (DES) Implantation in Left anterior Descending artery with TIMI III flow, 3e: Coronary Guide Wire with Microcatheter in Left circumflex artery, 3f: Coronary guide wire crossed the CTO and parked in major obtuse marginal, 3g: Final result of left circumflex artery post DES implantation, 3h: Final result post stent implantation in LAD and LCx arteries



Fig. 4. Echocardiogram images showing mild mitral regurgitation (post revascularization).

hospital mortality [1].The medical stabilization in mechanical complications like ventricular septal rupture after ACS has been well described [25]. Management of patients with CS and MODS requires intensive care with support of failing organs including lungs and kidneys [26]. The role of parentral antiplatelets in emergency PCI has been studied in emergency settings when oral absorption of drugs is doubtful. Intravenous infusion of glycoprotein IIB/IIIA inhibitors and stenting were independently associated with improved outcomes in CS [27]. We used Tirofiban infusion (in renal modified dosages) in our patient prior to angioplasty which might have influenced the outcome, as we were not confident about the adequate absorption of oral drugs during the initial phase of admission. The patient was taken up for angiography and angioplasty only after hemodynamic stabilization and could achieve optimal technical results.

4. CONCLUSION

This case highlights the challenges faced during management of ACS patients with CS, who present late after the symptom onset. This is one of those patients where we did not pursue the urgent coronary angiography & revascularization; rather we improved the hemodynamics conservatively followed by definite management. The existing literature and guidelines on management of patients who present late after myocardial infarction and have CS, are highly insufficient and require further studies.

CONSENT

As per international standard or university standard, patient's written consent has been collected and preserved by the author(s).

ETHICAL APPROVAL

As per international standard or university standard written ethical approval has been collected and preserved by the author(s).

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Sharma YP, Krishnappa D, Kanabar K, Kasinadhuni G, Sharma R, Kishore K, et al. Clinical characteristics and outcome in patients with a delayed presentation after ST-elevation myocardial infarction and complicated by cardiogenic shock. Indian Heart J. 2019;71(5):387-93. Available:https://doi.org/10.1016/j.ihj.2019.11.256
2. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock: SHOCK investigators: should we emergently revascularize occluded

coronaries for cardiogenic shock. N Engl J Med. 1999;341:625-634.

3. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA. 2006;295:2511-2515.
4. Hochman JS, Boland J, Sleeper LA, et al. Current spectrum of cardiogenic shock and effect of early revascularization on mortality: results of an international registry. Circulation 1995;91:873-881
5. Urban P, Stauffer JC, Bleed D, et al. A randomized evaluation of early revascularization to treat shock complicating acute myocardial infarction: the (Swiss) multicenter trial of angioplasty for shock -- (S)MASH. Eur Heart J. 1999;20:1030-1038
6. Tiefenbrunn AJ, Chandra NC, French WJ, Gore JM, Rogers WJ. Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2). J Am CollCardiol. 1998;31:1240-1245
7. Berger PB, Holmes DR Jr, Stebbins AL, Bates ER, Califf RM, Topol EJ. Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial: an observational study. Circulation. 1997; 96:122-127.
8. Menon V, Hochman JS, Holmes DR Jr, et al. Lack of progress in cardiogenic shock: lessons from the GUSTO trials. J Am CollCardiol. 1998;31:Suppl A:136A-136A abstract.
9. Goldberg RJ, Gore JM, Alpert JS, et al. Cardiogenic shock after acute myocardial infarction: incidence and mortality from a community-wide perspective, 1975 to 1988. N Engl J Med. 1991;325:1117-1122
10. Killip T III, Kimball JT. Treatment of myocardial infarction in a coronary care unit: a two year experience with 250 patients. Am J Cardiol. 1967;20:457-464
11. Sharma YP, Krishnappa D, Kanabar K, Kasinadhuni G, Sharma R, Kishore K, et al. Clinical characteristics and outcome in patients with a delayed presentation after ST-elevation myocardial infarction and complicated by cardiogenic shock. Indian Heart J. 2019;71(5):387-93. Available:https://doi.org/10.1016/j.ihj.2019.11.256
12. Xavier D, Pais P, Devereaux PJ, Xie C, Prabhakaran D, Reddy KS, Gupta R, Joshi P, Kerkar P, Thanikachalam S, Haridas KK, Jaison TM, Naik S, Maity AK, Yusuf S; CREATE registry investigators. Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. Lancet. 2008 Apr 26;371(9622):1435-42. DOI: 10.1016/S0140-6736(08)60623-6. PMID: 18440425.
13. Cerrato E, Forno D, Ferro S, Chinaglia A. Characteristics, in-hospital management and outcome of late acute ST-elevation myocardial infarction presenters. J Cardiovasc Med (Hagerstown). 2017; 18(8):567-71. DOI: 10.2459/jcm.0000000000000527
14. Mahmud E, Dauerman HL, Welt FG, Messenger JC, Rao SV, Grines C, Mattu A, Kirtane AJ, Jauhar R, Meraj P, Rokos IC, Rumsfeld JS, Henry TD. Management of acute myocardial infarction during the COVID-19 pandemic. Journal of the American College of Cardiology; 2020. DOI:https://doi.org/10.1016/j.jacc.2020.04.039.
15. Zeng J, Huang J, Pan L. How to balance acute myocardial infarction and COVID-19: the protocols from Sichuan Provincial People's Hospital. Intensive Care Med. 2020 Mar 11;1–3. DOI: 10.1007/s00134-020-05993-9. Epub ahead of print. PMID: 32162032; PMCID: PMC7079823.
16. Wackers FJ, Lie KI, Becker AE, Durrer D, Wellens HJ. Coronary artery disease in patients dying from cardiogenic shock or congestive heart failure in the setting of acute myocardial infarction. Br Heart J. 1976;38:906–10.
17. Hochman JS, Buller CE, Sleeper LA, Boland J, Dzavik V, Sanborn TA, et al. Cardiogenic shock complicating acute myocardial infarction— etiologies, management and outcome: a report from the SHOCK Trial Registry. J Am CollCardiol. 2000;36:1063–70.
18. Singh M, White J, Hasdai D, Hodgson PK, Berger PB, Topol EJ, et al. Long-term outcome and its predictors among patients with st-segment elevation myocardial

infarction complicated by shock: insights from the GUSTO-I Trial. J Am CollCardiol. 2007;50(18):1752-8.
Available:https://doi.org/10.1016/j.jacc.2007.04.101

19. Kohsaka S, Menon V, Lowe AM, Lange M, Dzavik V, Sleeper LA, et al. Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock. Arch Intern Med. 2005;165(14):1643-50.
10.1001/archinte.165.14.1643
20. Brunkhorst FM, Clark AL, Forycki ZF, Anker SD. Pyrexia, procalcitonin, immune activation and survival in cardiogenic shock: the potential importance of bacterial translocation. Int J Cardiol. 1999;72(1):3-10. 10.1016/s0167-5273(99)00118-7
21. Goldberg RJ, Gore JM, Alpert JS, Osganian V, de Groot J, Bade J, et al. Cardiogenic Shock after Acute Myocardial Infarction. New Engl J Med. 1991;325(16):1117-22.
10.1056/NEJM199110173251601
22. Goldberg RJ, Spencer FA, Gore JM, Lessard D, Yarzebski J. Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective. Circulation. 2009;119(9):1211-9.
10.1161/CIRCULATIONAHA.108.814947
23. Stone GW, Brodie BR, Griffin JJ, Morice MC, Costantini C, St. Goar FG, et al. Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction: In-hospital and 30-day results of the PAMI Stent Pilot Trial fn1fn1Funding for this study was provided in part by an unrestricted grant from Johnson & Johnson Interventional Systems, Warren, New Jersey. J Am CollCardiol. 1998;31(1):23-30.
Available:https://doi.org/10.1016/S0735-1097(97)00439-7
24. Steg PG,Bonnefoy E, Chabaud S, Lapostolle F, Dubien PY, Cristofini P, et al. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation. 2003; 108(23):2851-6.
10.1161/01.Cir.0000103122.10021.F2
25. Sharma YP, Kamana NK, Vadivelu R. Precision in cardiology: should all cases of myocardial infarction with ventricular septal rupture require early repair? Heart Asia. 2013;5(1):235-7. 10.1136/heartasia-2012-010219
26. Reynolds Harmony R, Hochman Judith S. Cardiogenic shock. Circulation. 2008; 117(5):686-97.
10.1161/CIRCULATIONAHA.106.613596
27. Klein LW, Shaw RE, Krone RJ, Brindis RG, Anderson HV, Block PC, et al. Mortality after emergent percutaneous coronary intervention in cardiogenic shock secondary to acute myocardial infarction and usefulness of a mortality prediction model. American Journal of Cardiology. 2005;96(1):35-41.
10.1016/j.amjcard.2005.02.040

Peer-review history:
The peer review history for this paper can be accessed here:
http://www.sdiarticle4.com/review-history/67253